![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » TWO NEW PATENTS ISSUED TO ENTREMED
TWO NEW PATENTS ISSUED TO ENTREMED
August 17, 2005
EntreMed announced the issuance of two U.S. patents covering its lead clinical-stage
compound, 2- methoxyestradiol (2ME2) and multiple derivatives of 2ME2. 2ME2
(Panzem capsules and Panzem NCD) is currently in clinical trials for cancer,
as well as in preclinical development for inflammatory disorders.
The patents grant EntreMed intellectual property protection for 2ME2 and derivatives
of 2ME2 in oncology and a broad range of non-oncology indications, including
inflammatory disorders, immune disorders, cardiovascular disorders, and rheumatoid
arthritis.
2ME2 is a novel anticancer agent, which is part of a next generation of antimitotic
cancer drugs that bind to tubulin and work through multiple cellular pathways.
2ME2 can attack tumors on multiple fronts - by disrupting microtubules, an intracellular
matrix necessary for the rapid division of cancer cells (mitosis), by inducing
programmed cell death (apoptosis), and by blocking blood vessels that feed tumors
(angiogenesis inhibition).
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct